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HDAC6 is a unique histone deacetylase that targets cytoplasmic non-histone proteins
and has a specific ubiquitin-binding activity. Both of these activities are required for
HDAC6-mediated formation of aggresomes, which contain misfolded proteins that will
ultimately be degraded via autophagy. HDAC6 deacetylase activity is increased following
phosphorylation on serine 22 (phospho-HDAC6). In human, HDAC6 localizes in neuronal
Lewy bodies in Parkinson’s disease (PD) and in oligodendrocytic Papp–Lantos bodies
in multiple system atrophy (MSA). However, the expression of phospho-HDAC6 in post-
mortem human brains is currently unexplored. Here, we evaluate and compare the
distribution of HDAC6 and its phosphorylated form in human brains obtained from
patients affected by three forms of parkinsonism: two synucleinopathies (PD and MSA)
and a tauopathy (progressive supranuclear palsy, PSP). We find that both HDAC6
and its phosphorylated form localize with pathological protein aggregates, including
α-synuclein-positive Lewy bodies in PD and Papp–Lantos bodies in MSA, and phospho-
tau-positive neurofibrillary tangles in PSP. We further find a direct interaction of HDAC6
with α-synuclein with proximity ligation assay (PLA) in neuronal cell of PD patients. Taken
together, our findings suggest that both HDAC6 and phospho-HDAC6 regulate the
homeostasis of intra-neuronal proteins in parkinsonism.
Keywords: HDAC6, phosphorylated-HDCA6, protein aggregation, α-synuclein, tau, Parkinson’s disease,
parkinsonism
INTRODUCTION
Histone deacetylases (HDACs) belong to a family of enzymes closely associated with gene
expression and chromatin dynamics. Among them, HDAC6 is a well-characterized class II HDAC
showing particular structural features and a number of domains that interact with specific,
non-histone substrates (Valenzuela-Fernández et al., 2008). HDAC6 functions are mediated by two
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catalytic deacetylase domains (DD1 and DD2) and a C-terminal
zinc finger ubiquitin-binding domain, which allows HDAC6 to
bind mono- and poly-ubiquitin chains with high affinity (Hook
et al., 2002; Boyault et al., 2006). HDAC6 cytoplasmic localization
is regulated by a SE14 domain (Bertos et al., 2004) and a nuclear
export signal (NES), which enables HDAC6 to accumulate in the
cytoplasm (Verdel et al., 2000). HDAC6 dynein-binding domain
(DMB) enables the dynein-mediated transport of ubiquitinated
proteins along microtubules (Richter-Landsberg and Leyk, 2013).
The distinct functions of HDAC6 rely on its deacetylase and
ubiquitin-binding activity.
In the cytoplasm, HDAC6 deacetylase activity targets
mainly non-histone proteins (Richter-Landsberg and Leyk,
2013). Moreover, HDAC6 is the major microtubule-associated
deacetylase responsible for microtubule acetylation (Hubbert
et al., 2002). Alpha-tubulin acetylation of lysine 40 only occurs
on polymerized microtubules (Matsuyama et al., 2002). While
still controversial, there is evidence that HDAC6 preferentially
acts on free tubulin dimer (Matsuyama et al., 2002; Skultetyova
et al., 2017). An increase in microtubule acetylation stimulates
anterograde and retrograde transport processes via kinesin-1
and dynein recruitment (Dompierre et al., 2007). Nevertheless,
the HDAC6 deacetylase function is inhibited by tau (Perez et al.,
2009). Tau is sensitive to acetylation, and its hyper-acetylation
leads to fibrillization in vitro and also microtubule assembly
impairment. Interestingly, tau itself was identified as one of
the HDAC6 targets (Cohen et al., 2011). Importantly, HDAC6
deacetylase activity is increased after serine 22 phosphorylation
by glycogen synthase kinase 3β (Chen et al., 2010).
HDAC6 ubiquitin-binding activity is well characterized in
neurodegenerative disorders, including Parkinson’s disease (PD),
Alzheimer’s disease (AD), and Huntington’s disease (Simões-
Pires et al., 2013). The formation of intracellular aggregates
containing misfolded proteins is a cellular hallmark of several
neurodegenerative diseases. In eukaryotes, ubiquitin-proteasome
system (UPS) and autophagy are the two main degradation
pathways that clear misfolded proteins. A close relationship
exists between the UPS and autophagy, since autophagy may
act as a compensatory mechanism in case of UPS impairment
(Pandey et al., 2007). In neurodegenerative disorders, many
ubiquitinated proteins accumulate, leading to saturation of UPS
(Thibaudeau et al., 2018). In this context, HDAC6 acts as a
cellular stress sensor and coordinates cell responses to fight
accumulation of cytotoxic protein aggregates. Thus, HDAC6
interacts with dynein and promotes the retrograde transport
of misfolded proteins to aggresome (Kawaguchi et al., 2003).
Aggresome is a cytosolic structure enriched in polyubiquitin,
γ-tubulin, acetylated α-tubulin, HDAC6, and misfolded proteins
like α-synuclein (Richter-Landsberg and Leyk, 2013). Aggresome
formation has been linked to the biogenesis of inclusion bodies,
such as Lewy bodies in PD (Ardley et al., 2003; Kawaguchi et al.,
2003) and Papp–Lantos bodies in multiple system atrophy (MSA)
(Chiba et al., 2012). In addition, HDAC6 is involved in autophagy
where it regulates autophagosome maturation and fusion with
the lysosome (Richter-Landsberg and Leyk, 2013) through the
activation following deacetylation of the actin-remodeling factor
cortactin. This event causes the local assembly of a microfilament
network that enhances fusion activity and induces protein
aggregate degradation (Lee and Yao, 2010). HDAC6 also interacts
with tau through its SE14-domain and not with its ubiquitin
binding domain (Ding et al., 2008). This interaction leads to
the accumulation and colocalization of HDAC6 and tau in the
perinuclear region in an aggresome-like formation, especially
when proteasome is inhibited.
Here, we unraveled the distribution of HDAC6 and its
phosphorylated form in post-mortem human brains of PD and
primary atypical parkinsonism patients. Specifically, here we: (i)
evaluated the distribution of HDAC6 and its phosphorylated
form, phospho-HDAC6, in PD and atypical parkinsonisms,
such as MSA and PSP; (ii) analyzed the colocalization of
phospho-HDAC6 with α-synuclein and phospho-tau; and (iii)
checked for the interaction between phospho-HDAC6/HDAC6
and α-synuclein in PD.
MATERIALS AND METHODS
Human Brain Tissue
Post-mortem human brains obtained from patients fulfilling
clinical and neuropathological diagnostic criteria for PD (n = 5;
Braak stage VI of synuclein pathology) (Alafuzoff et al.,
2009), MSA (n = 1), PSP (n = 2), AD (n = 2), and from
control subjects (n = 4) were used (Supplementary Table S1;
Nervous Tissues Bank of Milan). Written informed consent was
obtained from all subjects in compliance with relevant laws
and institutional guidelines and approved by the appropriate
institutional committees. All the patients were enrolled and
followed during their disease by neurologists experienced in
movement disorders and dementia at Parkinson’s Centre ASST
G. Pini-CTO of Milan. The clinical diagnosis of PD was
established according to the UK Brain Bank criteria (Hughes
et al., 1992, 2001). The clinical diagnosis was confirmed by
neuropathological analysis carried out according to the current
BrainNet Europe Consortium guidelines (Alafuzoff et al., 2009;
Dickson and Weller, 2011) by two experts (GGi and MB).
Control subjects were clinically free from neurological diseases.
Brains were fixed in 10% buffered formalin for at least 1 month
at 20◦C. After dehydration and clearing steps, selected areas
(medulla, mesencephalon, and entorhinal cortex) were embedded
in paraffin, and 5 µm thick sections were cut and processed for
the following analysis.
Immunofluorescence
Medulla, mesencephalon, and entorhinal cortex paraffin-
embedded sections were dewaxed in xylene and rehydrated.
Antigens were retrieved using 80% formic acid for 20 min
at room temperature. Before primary antibody incubation,
samples were incubated for 20 min with 1% BSA diluted in
0.01 M phosphate saline buffer (PBS) containing 0.1% Triton
X-100 (PBS-T). Primary antibodies (rabbit anti-HDAC6, 1:50,
GeneTex or rabbit anti-phospho-HDAC6, 1:50, GeneTex
and mouse anti-α-synuclein LB509, 1:500, Abcam or mouse
anti-phospho-tau AT8, 1:150, Thermo Fisher Scientific or
mouse anti-β-amyloid, 1:2000, Wako) in 1% BSA diluted
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in PBS-T were incubated overnight at room temperature.
After washing, samples were incubated for 2 h at room
temperature with highly pre-adsorbed secondary antibodies,
in particular Alexa Fluor R© 568 goat anti-mouse (Molecular
Probes) and Alexa Fluor R© 488 donkey anti-rabbit (Molecular
Probes). TO-PRO R©-3 (1:1000 for 10 min; Molecular Probes)
was used for nuclei counterstaining. Finally, samples were
mounted using 0.01 M PBS-glycerol (1:2) and examined
with a TCS SP8 confocal microscope Leica equipped with
an Argon laser coupled with a hybrid detector, a diode-
pumped solid-state laser coupled with a photomultiplier
tube and a helium/neon mixed gas laser coupled with a
hybrid detector.
Scan Acquisition and Colocalization
Analysis
In order to obtain images representative of the whole thickness
of the samples, immunostained slices were acquired using
the Hamamatsu Nanozoomer S60 scanner (Nikon) equipped
with an Olympus 20×/0.75 PlanSApo objective (Olympus), a
linear ORCA-Flash 4.0 digital CMOS camera (Hamamatsu), a
fluorescence imaging module equipped with a L11600 mercury
lamp (Hamamatsu), and two six-position filter wheels for
excitation and emission. The excitation filters used were 387/11
(DAPI), 480/17 (FITC), and 556/20 (TRITC). The quantitative
analysis of the acquired immunofluorescence images was
performed using ImageJ software (NIH). The areas analyzed
(dorsal motor nucleus of vagus, reticular nucleus, inferior
olivary nucleus, substantia nigra, red nucleus, and entorhinal
cortex) were previously selected using region of interest (ROI)
manager to produce an accurate ROI for the subsequent
analysis. The colocalization of α-synuclein and phospho-
tau with phospho-HDAC6 was determined by measuring
the Manders’ coefficients and Pearson’s correlation coefficient
(Bolte and Cordelières, 2006).
Proximity Ligation Assay (PLA)
The in situ proximity ligation assay (PLA) enables the detection
of protein–protein interactions in intact tissues (Söderberg
et al., 2006; Longhena et al., 2018). For PLA procedure,
we analyzed human paraffin-embedded brain sections from
the substantia nigra of PD patients and controls using
the Duolink assay kit (Sigma Aldrich) according to the
manufacturer’s instructions. Briefly, after dehydration, samples
were treated as described for immunohistochemistry (formic
acid, BSA/PBS-T as blocking solution) and incubated with the
same mix of primary antibodies (rabbit anti-HDAC6/mouse
anti-α-synuclein LB509 and rabbit anti-phospho-HDAC6/mouse
anti-α-synuclein LB509). After washing, samples were incubated
with the goat anti-mouse IgG and anti-rabbit IgG secondary
antibodies conjugated, respectively, with Duolink R© PLA MINUS
and PLUS oligonucleotides in Duolink R© antibody diluent for
2 h at 37◦C. Samples were then treated with a solution
of Duolink R© ligation solution (1:5) and Duolink R© ligase
(1:40) at 37◦C for 1 h. After that, samples were incubated
with a solution of Duolink R© amplification reagent green
1:5 and Duolink R© polymerase (1:80) at 37◦C for 2.5 h.
Finally, TO-PRO R©-3 was used for nuclei counterstaining.
The samples were mounted using Mowiol R©(Calbiochem)-
DABCO (Sigma). PLA-labeled samples were examined with
a TCS SP8 confocal microscope. In order to analyze PLA
puncta/neuron, we acquired four images (20× magnification)
for each PD patient and control (PLA HDAC6/α-synuclein:
PD n = 3, controls n = 3; PLA p-HDAC6/α-synuclein:
PD n = 4, controls n = 4). PLA puncta were quantified
in the neuronal cell bodies containing neuromelanin, as
revealed by phase contrast microscopy, using ImageJ (Cell
Counter plugin).
Statistical Analysis
Statistical comparisons were conducted by the Mann-Whitney
(control subjects n = 4; PD patients n = 4) or Student’s t-test
for PLA puncta/neuron. Statistical significance was assessed
using GraphPad Prism software. Significance was established
at p< 0.05.
RESULTS
Phospho-HDAC6 Localizes in Lewy
Bodies of PD Patients
To investigate the relationship between HDAC6 and α-synuclein,
we performed double immunofluorescence on PD patient brain.
We initially focused on the substantia nigra that is the first
brain region directly linked to the motor symptoms during
PD progression. We found that HDAC6 is highly expressed
in the substantia nigra neurons that contain α-synuclein
positive Lewy bodies. Interestingly, HDAC6 strongly colocalized
with Lewy bodies (Figures 1A–A”), while in control subjects
the HDAC6 staining is weak and diffuse in the cytoplasm
(Figure 1A”’). The same expression pattern was observed
in other brain areas involved in PD progression, including
the entorhinal cortex (Figures 1B–B”), the dorsal motor
nucleus of vagus (Supplementary Figures S1A–A”) and the
locus coeruleus (Supplementary Figures S1B–B”). In the
entorhinal cortex, HDAC6 expression was not restricted to cells
containing Lewy bodies, but it was present in the majority of
neurons (Figures 1B–B”) while it is almost undetectable in
controls (Figure 1B”’).
We evaluated for the first time the distribution of phospho-
HDAC6 in α-synuclein inclusion bodies, and we performed
double immunofluorescence for α-synuclein and phospho-
HDAC6 in PD and control brains. In the substantia nigra,
phospho-HDAC6 was almost undetectable in neuronal
cell bodies of control subjects (Figures 1C”’,D”’), while it
showed a neuronal punctate staining in PD brains where it
mainly colocalized with α-synuclein-positive Lewy bodies
(Figures 1C–C”). In addition, phospho-HDAC6 staining
appeared scattered in the neuropil. The same distribution was
observed in the dorsal motor nucleus of vagus (Supplementary
Figures S1C–C”) and locus coeruleus (Supplementary
Figures S1D–D”). Notably, cortical Lewy bodies also
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FIGURE 1 | Lewy bodies contain both HDAC6 and phospho-HDAC6 in substantia nigra and entorhinal cortex of PD patients. Confocal microscopy analysis shows
that HDAC6 staining [green in (A,A”,B,B”)] is abundant in neuronal cell bodies which present α-synuclein positive Lewy bodies [red in (A’,A”,B’,B”); white arrows].
Notably, in entorhinal cortex, HDAC6 staining is also present in the majority of neurons. In control subjects (A”’,B”’), HDAC6 staining is point and weak in the
cytoplasm. Phospho-HDAC6 [green in (C,C”,D,D”)] is present as punctate staining in neuronal cell bodies, and it accumulates into α-synuclein positive Lewy bodies
[red in (C’,C”,D’,D”)], while it is almost undetectable in neuronal cell bodies in controls (C”’,D”’). Nuclei were counterstained using TOPRO-3 (blue). Scale bar,
25 µm.
contained phospho-HDAC6, as shown in entorhinal cortex
(Figures 1D–D”).
Phospho-HDAC6 Accumulates in
Papp–Lantos Bodies of an MSA Patient
To test whether phosphorylated HDAC6 accumulation in
Lewy bodies is restricted to PD, we evaluated the expression
of phospho-HDAC6 in other parkinsonisms. We performed
double immunofluorescence for α-synuclein and phospho-
HDAC6 on one patient affected by MSA, a synucleinopathy
characterized by the presence of α-synuclein aggregates mainly
in oligodendrocytes. We focused on inferior olivary nucleus
(Figure 2) and putamen (not shown), two regions enriched
in white matter and therefore in oligodendrocytes. In controls,
phospho-HDAC6 was absent in neuronal cell bodies and in all
the glial cells (Figure 2A”’), while it was present in neuropil. In
an MSA patient, oligodendrocytes showed the typical triangular
or flame-shaped α-synuclein aggregates, known as Papp–Lantos
inclusions (Figure 2A’). Double immunostaining for phospho-
HDAC6 and α-synuclein revealed that some oligodendrocytes
contained both inclusion bodies of α-synuclein and intense
phospho-HDAC6 staining (Figure 2A”). On the contrary,
in the neuronal cell bodies of the inferior olivary nucleus,
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phospho-HDAC6 was absent (Figure 2A). All together, these
data suggest that phospho-HDAC6 colocalizes with α-synuclein
aggregates not only in PD but also in MSA.
Phospho-HDAC6 and Phospho-Tau
Colocalize in Inferior Olivary Nucleus in
PSP
Since phospho-HDAC6 is present in α-synuclein inclusion
bodies of PD and also in the MSA patient, we asked whether
phospho-HDAC6 could also be linked to protein aggregation in
neurodegenerative diseases beyond synucleinopathies.
Phospho-tau is the main component of neurofibrillary
tangles, pathological hallmarks of tauopathies (Dickson
and Weller, 2011). To test whether phospho-HDAC6
localized in neurofibrillary tangles, we performed double
immunofluorescence for phospho-HDAC6 and phospho-tau in
atypical parkinsonism PSP. Histopathological analysis confirmed
that α-synuclein aggregates were absent in the brain of PSP
patients (data not shown). We analyzed the inferior olivary
nucleus where neurofibrillary tangles accumulate in PSP brain
(Dickson and Weller, 2011). We found an intense and diffuse
phospho-HDAC6 staining in neuronal cell bodies and within
PSP neurofibrillary tangles, which displayed strong phospho-tau
staining (Figures 2B–B”), whereas controls were negative
(Figure 2B”’).
Phospho-HDAC6 consistently localized with cytoplasmic
protein aggregates in PD, MSA, and PSP. To evaluate whether
phospho-HDAC6 identified both intra- and extra-neuronal
protein aggregates in neurodegenerative diseases, we analyzed
AD human brains. Interestingly, phospho-HDAC6 staining was
absent in extra-neuronal amyloid beta plaques in entorhinal
cortex (Figures 2C–C”) as well as in controls (Figure 2C”’). All
together, these results indicate that phospho-HDAC6 identifies
exclusively intracellular protein aggregates.
Specific Distribution of Phospho-HDAC6
in Parkinsonisms
To investigate phospo-HDAC6 accumulation and protein
aggregation in parkinsonism, we extended our analysis to the
medulla, midbrain, and cortex of PD, MSA, and PSP patients
(Figures 3A–C’ and Supplementary Figure S2).
We evaluated the fraction of phospho-HDAC6 colocalizing
with α-synuclein in PD and MSA brains. Phospho-HDAC6 and
α-synuclein significantly colocalized in the dorsal motor nucleus
of vagus, substantia nigra, red nucleus, and entorhinal cortex
in PD compared to controls (Figure 3D). These brain regions
are heavily affected by α-synuclein pathology at the analyzed
time point (Braak stage VI) (Dickson and Weller, 2011). On the
contrary, phospho-HDAC6 and α-synuclein did not colocalize in
the reticular formation and in the inferior olivary nucleus that is
widely unaffected in PD patients.
MSA neurodegeneration largely affects highly myelinated
regions (Dickson and Weller, 2011). In line with this, we
analyzed samples from one MSA patient and found high
colocalization of phospho-HDAC6 and α-synuclein in inferior
olivary nucleus, dorsal motor nucleus of vagus, and reticular
formation (Figure 3E). On the contrary, in the substantia nigra
of the MSA patient, phospho-HDAC6/α-synuclein colocalization
was not different from control (Figure 3E vs. 3D), this can
be explained with the advanced neurodegenerative state of this
region at the final stage of the disease. Interestingly, phospho-
HDAC6 and α-synuclein colocalization was undetectable in
entorhinal cortex of MSA and control subjects (Figure 3E).
The analysis of the two PSP patients suggests an increase
in the colocalization of phospho-HDAC6 and phospho-tau in
the dorsal motor nucleus of vagus, inferior olivary nucleus, and
reticular formation (Figure 3F). We also evaluated the fraction
of α-synuclein and phospho-tau that colocalized with phospho-
HDAC6 in the brain regions previously analyzed. Overall, we
found that α-synuclein extensively colocalized with phospho-
HDAC6 in PD (Manders’ coefficient: 72–99%) and to a less
extent in the MSA patient (Manders’ coefficient: 43–70%).
Furthermore, phospho-tau widely colocalized with phospho-
HDAC6 in PSP (Manders’ coefficient: 60–87%). Mander’s
colocalization analysis is also supported by Pearson’s coefficient
study (Supplementary Table S3).
HDAC6 and Phospho-HDAC6 Interact
With α-Synuclein in PD
To unravel the direct interactions between HDAC6 and cellular
aggregate components, we employed a PLA approach to
detect HDAC6/α-synuclein and phospho-HDAC6/α-synuclein
interactions in substantia nigra neurons of PD patients
and controls. While HDAC6/α-synuclein PLA signal was
undetectable or scarce in neuromelanin-containing cell bodies
in control brains (Figures 4A,A’,C), it showed a scattered profile
in the neuropil and a significantly increased punctate staining
within neuronal cell bodies in PD brain (Figures 4B,B’,C).
Interestingly, also phospho-HDAC6/α-synuclein PLA signal
was undetectable or scarce in controls (Figures 4D,D’,F),
whereas it was significantly increased in substantia nigra
neurons of PD (Figures 4E,E’,F). These data clearly indicate
the direct interaction of HDAC6 and phospho-HDAC6 with
α-synuclein in PD brain.
HDAC6 localization in aggresome hinges on retrograde
transport (Kawaguchi et al., 2003). We showed here that
HDAC6 and phospho-HDAC6 interact with α-synuclein and
we therefore tested the involvement of phospho-HDAC6 in
the retrograde transport of α-synuclein. We evaluated the
expression of α-synuclein, phospho-HDAC6, and the motor
protein dynein in control (Supplementary Figure S3A–A”’)
and PD (Supplementary Figure S3B–B”’) brains and found
that phospho-HDAC6 colocalization with α-synuclein and
dynein significantly increased in PD patients (Supplementary
Figure S3C), thus suggesting trafficking alterations.
DISCUSSION
Despite intra- and extra-neuronal protein aggregates are
hallmarks of many neurodegenerative disorders, their exact
composition and the molecular mechanisms leading to their
formation are still unclear. In this study, we investigated the role
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FIGURE 2 | Phospho-HDAC6 gathers into protein aggregates in inferior olivary nucleus of MSA and PSP, but not in entorhinal cortex of AD patients. In MSA (A–A”),
numerous Papp–Lantos inclusions in oligodendrocytes, which are positive for α-synuclein (red), show phospho-HDAC6 staining (green, white arrows). In PSP
patients (B–B”), phospho-HDAC6 (green) is present as punctate staining in neuronal cell bodies, (white arrowhead). Neurons also present aggregates of
phospho-tau (visualized using AT8 antibody, red) known as neurofibrillary tangles (B’,B”), which resulted to be positive for phospho-HDAC6 (green) as indicated by
white arrows. Phospho-HDAC6 staining was absent in amyloid beta protein positive plaques in entorhinal cortex in AD patients (C–C”). In controls (A”’,B”’,C”’),
phospho-HDAC6 is negative in both neuronal (visible for the presence of lipofuscin; asterisks) and glial cell bodies and the neuropil is poorly stained. α-Synuclein is
present only with its characteristic synaptic pattern (A”’). Phospho-tau and amyloid beta protein are absent in controls, respectively, in the inferior olivary nucleus
(B”’) and in entorhinal cortex (C”’). Samples were counterstained using TOPRO-3 (blue). Scale bar, 25 µm.
of HDAC6 and its phosphorylated version in PD and in atypical
parkinsonism MSA and PSP. Besides confirming the presence
of HDAC6 in PD and in the MSA patient, we showed for the
first time that phospho-HDAC6 localizes in Lewy bodies where
it interacts with α-synuclein in PD.
We compared the expression of phospho-HDAC6 in PD,
the synucleinopathy MSA, and the tauopathy PSP. Interestingly,
phospho-HDAC6 is expressed in Papp–Lantos bodies in
the MSA patient and in neurofibrillary tangles of PSP
patients, while it was absent in extra-neuronal amyloid beta
plaques in AD brains. Despite the limitation of a small
patient cohort and the need of confirmation in future
larger studies, all the subjects included in this article have
been accurately checked for both clinical diagnosis and
neuropathological analysis. On this basis, our results suggest
that phospho-HDAC6 could be a common hallmark in the
formation of intracellular protein aggregates in different forms
of parkinsonisms.
α-Synuclein is the main component of the typical inclusion
bodies that are linked to neurodegeneration in synucleinopathies,
such as PD and MSA (Dickson et al., 2009; Goedert et al., 2017).
The identification of α-synuclein interacting partners has a
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FIGURE 3 | Fraction of phospho-HDAC6 colocalizing with α-synuclein or phospho-tau. Areas that underwent quantification procedure are highlighted in (A–C) (red
areas), which stand for a schematic representation of, respectively, (A’–C’) (brightfield images obtained from scanner acquisition). Colocalization rates are evaluated
as M1 Mander’s coefficient between phospho-HDAC6 and α-synuclein in PD compared to control (D) and in MSA (E) or phospho-tau in PSP (F). Values are
expressed as intervals (indicated in the Supplementary Table S2) that consider inter-individual variability. DMV, dorsal motor nucleus of vagus; EC, entorhinal cortex;
ON, olivary nucleus; pHDAC6, phospho-HDAC6; pTau, phospho-tau; RF, reticular formation; RN, red nucleus; SN, substantia nigra. Mann-Whitney test *p < 0.05.
major implications for elucidating the neurodegenerative process
(Yan et al., 2018). We therefore investigated the interplay
of α-synuclein with HDAC6 and its phosphorylated active
version phospho-HDAC6 (Chen et al., 2010). To date, the
data available on HDAC6 expression in post-mortem PD
patient brain indicate that it accumulates into Lewy bodies
in cerebral cortex (Kawaguchi et al., 2003). Here, we first
confirmed that HDAC6 gathers into α-synuclein-positive Lewy
bodies in cerebral cortex. We also extended the analysis to
neuromelanin-containing neurons in substantia nigra, locus
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FIGURE 4 | Confocal analysis of PLA for HDAC6 and α-synuclein and for phospho-HDAC6 and α-synuclein in substantia nigra in control and PD patients. PLA
signal (green) for both HDAC6/α-synuclein and phospho-HDAC6/α-synuclein is present as punctate diffuse staining within neuronal cell bodies in PD patients (B,E)
as indicated by white arrows, while it is absent or scarce in controls (A,D). Magnification, 1.25×. Samples were counterstained using TOPRO-3 (blue). In
(A’,B’,D’,E’), the images show the blue channel; besides nuclei staining, there is evident tissue autofluorescence (arrowheads), which enables the exclusion of
aspecific staining and to identify the specific PLA signal (arrows). (C,F) Quantifications of PLA puncta/SN neuron containing neuromelanin identifiable with the phase
contrast superimposed image ± SEM (n = 3–4 per groups; analyzed neurons: n = 18–44 for groups; **p = 0.01; ***p = 0.001). Scale bar, 25 µm.
coeruleus, and dorsal motor nucleus of vagus in post-mortem
PD brain. In all these regions, HDAC6 was expressed in Lewy
bodies, and it is therefore a hallmark for brain areas affected by
α-synuclein pathology.
Further, we evaluated the expression of phospho-HDAC6
in PD and found that is restricted to Lewy bodies. In
addition, PLA experiments showed that both HDAC6 and
phospho-HDAC6 directly interacted with α-synuclein.
This close interaction strongly suggests the importance of
HDAC6 and phospho-HDAC6 in protein aggregation during
neurodegeneration.
There is evidence about the involvement of HDAC6 in
cellular management of misfolded protein and macroautophagy
(reviewed in Richter-Landsberg and Leyk, 2013; Simões-Pires
et al., 2013; Yan, 2014). In vitro experiments demonstrate that
HDAC6 promotes the retrograde transport of polyubiquitinated
misfolded proteins to the aggresome, via the interaction
with dynein motor. Moreover, HDAC6 knock-down impairs
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aggresome formation and clearance of misfolded protein
aggregates from the cytoplasm (Kawaguchi et al., 2003).
Therefore, HDAC6 can support proper protein homeostasis and
be neuroprotective (Zheng et al., 2013; Bourque et al., 2014;
Du et al., 2014). The role of HDAC6 in neurodegeneration
is still controversial. In animal experimental models of PD
and Huntington’s diseases, HDAC6 inhibition rescues axonal
transport defects and is beneficial for the neuronal survival
(Dompierre et al., 2007; Godena et al., 2014; Pinho et al.,
2016; Jian et al., 2017). HDAC6 inhibition also provides
protection against oxidative stress on neurons in vitro (Leyk
et al., 2017). On the other hand, HDAC6 knock-down impairs
aggresome formation and clearance of misfolded protein
aggregates causing cell death in vitro (Kawaguchi et al., 2003).
Therefore, HDAC6 could support proper protein homeostasis
and be neuroprotective (Zheng et al., 2013; Bourque et al., 2014;
Du et al., 2014). To shed light on this complex mechanism,
we addressed the role of HDAC6 and its phosphorylation
ex vivo in human brain samples. In line with HDAC6 beneficial
role, our current data indicate that HDAC6 could have a
protective function during neurodegeneration. Indeed, we found
an increase of HDAC6 and phospo-HDAC6 in PD, MSA, and PSP
patients. Considering that HDAC6 phosphorylation increases
its deacetylase activity (Chen et al., 2010) that is implicated in
aggresome formation (Kawaguchi et al., 2003), increased HDAC6
levels could be the results of a compensatory mechanism for
misfolded protein degradation.
Neurodegenerative diseases are characterized by specific types
of protein aggregates. For example, MSA is a synucleinopathy
characterized by α-synuclein aggregation in oligodendrocytes.
PSP is a tauopathy where phospho-tau aggregates in neurons,
while amyloid beta plaques in AD exist as extracellular aggregates
(Dickson and Weller, 2011). We found that phospho-HDAC6
colocalized with α-synuclein in MSA and phospho-tau in
PSP but not with extra-neuronal amyloid aggregates in
AD. These data come from few patients and we are aware
that need to be replicated in a bigger cohort. However, this
restricted expression pattern could indicate that phospho-
HDAC6 accumulation is not a ubiquitous marker of protein
aggregates. To note, phospho-HDAC6 selectively identifies
cells in disease-specific manner (glia in MSA and neurons
in PSP). Taken together, our results suggest that HDAC6
phosphorylation is specifically involved in pathological and
intra-cellular protein aggregation occurring in parkinsonisms.
While MSA-related Papp–Lantos inclusions are HDAC6
positive (Miki et al., 2011), here we provide a comprehensive
analysis of phospho-HDAC6 distribution in several brain
areas of the MSA patient and the two PSP patients. We also
determined the fraction of phospho-HDAC6 colocalizing with
α-synuclein or phospho-tau. We found area- and disease-
specific changes in colocalization between phospho-HDAC6
and α-synuclein. In particular, the olivary nucleus, a region
in which Lewy bodies are absent in PD, lacks phospho-
HDAC6 positive α-synuclein aggregates in control and PD
subjects. On the contrary, the same region that is affected in
MSA phospho-HDAC6 and α-synuclein heavily colocalize in
Papp–Lantos bodies.
Several lines of evidence support the idea that many
points of convergence exist among parkinsonisms. For example,
α-synuclein and tau aggregations co-occur in a spectrum of
neurodegenerative disorders (Lippa et al., 1998; Hamilton, 2000;
Judkins et al., 2002; Mori et al., 2002; Yancopoulou et al.,
2005). Another interesting point linking α-synuclein to tau is
that mutations in the SNCA and MAPT genes can both lead
to neurodegenerative disorders characterized by parkinsonism
(Polymeropoulos et al., 1997; Dumanchin et al., 1998; Spillantini
et al., 1998; Fujioka et al., 2014). In addition, we propose
that HDAC6 could be considered as a common hallmark
of parkinsonisms, independently from the nature of protein
aggregates (Lewy bodies, Papp–Lantos bodies, and neurofibrillary
tangles) and affected cells (neurons and glia). HDAC6 and
phospho-HDAC6 gather into protein aggregates in PD, MSA,
and PSP. Moreover, HDAC6 was already been established as a
partner of tau in AD (Ding et al., 2008; Cook et al., 2012), and,
interestingly, tau protein interacts and regulates the activity of
HDAC6 (Simões-Pires et al., 2013).
Further analysis will aim to provide new insights into the
complex role of the HDAC6 phosphorylation in controlling
neurodegeneration in PD and parkinsonism.
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